What is Precision BioScience?
Precision BioScience is a biotechnology firm headquartered in Durham, North Carolina, dedicated to leveraging its proprietary genome editing technology. The company's core mission involves developing innovative solutions to combat cancers, cure genetic diseases, and enhance the development of more sustainable and productive food sources. Its advanced genome editing methods position it at the forefront of therapeutic and agricultural innovation.
How much funding has Precision BioScience raised?
Precision BioScience has raised a total of $321M across 4 funding rounds:
Series A
$25.6M
Series B
$110M
Debt
$40M
Stock Offering
$145.4M
Series A (2015): $25.6M with participation from F-Prime Capital Partners, venBio, Longevity Fund companies, Amgen Business Development, Osage University Partners, and Baxter International
Series B (2018): $110M led by ArrowMark Partners, Longevity Fund companies, Adage Capital Management, Osage University Partners, venBio, Leerink Partners, Amgen Business Development, Agent Capital, Pontifax AgTech, Cowen Healthcare Investments, Franklin Templeton Investments, DUMAC, RA Capital Management, Alexandria Venture Investments, Vivo Capital, Ridgeback Capital, Brace Pharma Capital, Gilead Sciences, OCV Partners, Cormorant Asset Management, and F-Prime
Debt (2019): $40M supported by Undisclosed
Stock Issuance/Offering (2019): $145.4M featuring Undisclosed
Key Investors in Precision BioScience
venBio
venBio is a life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs. Founded in 2011, the firm manages nearly $1.1 billion in committed capital and emphasizes the importance of positioning its portfolio companies for potential acquisition.
Longevity Fund companies
The Longevity Fund is a venture capital firm established in 2011, focused on funding companies that develop drugs for age-related diseases and longevity. The firm aims to support mission-oriented founders who are dedicated to creating innovative solutions in the longevity space.
Osage University Partners
Osage Venture Partners is a Philadelphia-based venture capital firm that specializes in investing in early-stage B2B software companies on the East Coast. The firm focuses on companies that are involved in the future of work and education, typically investing in post-revenue businesses with a revenue run rate between $500,000 and $3,000,000.
What's next for Precision BioScience?
With a history of significant enterprise-level funding and strategic investments, Precision BioScience is poised for continued expansion and development. The company's focus on critical areas such as oncology, genetic disease treatment, and agricultural advancement suggests a strategic roadmap aimed at translating its cutting-edge genome editing technology into tangible, impactful solutions. Future endeavors will likely involve further clinical trials, product development, and strategic partnerships to bring its innovations to market and address significant unmet needs.
See full Precision BioScience company page
